KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Other Non Operating Income (2016 - 2025)

Resmed (RMD) has disclosed Other Non Operating Income for 17 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 338.14% year-over-year to -$5.3 million, compared with a TTM value of -$14.2 million through Dec 2025, down 149.56%, and an annual FY2025 reading of -$5.3 million, down 50.43% over the prior year.
  • Other Non Operating Income was -$5.3 million for Q4 2025 at Resmed, down from -$3.8 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.7 million in Q1 2021 and bottomed at -$10.3 million in Q2 2021.
  • Average Other Non Operating Income over 5 years is -$1.4 million, with a median of -$1.6 million recorded in 2022.
  • Peak annual rise in Other Non Operating Income hit 423.32% in 2024, while the deepest fall reached 4947.54% in 2024.
  • Year by year, Other Non Operating Income stood at $841000.0 in 2021, then tumbled by 302.97% to -$1.7 million in 2022, then soared by 59.81% to -$686000.0 in 2023, then skyrocketed by 423.32% to $2.2 million in 2024, then plummeted by 338.14% to -$5.3 million in 2025.
  • Business Quant data shows Other Non Operating Income for RMD at -$5.3 million in Q4 2025, -$3.8 million in Q3 2025, and -$981000.0 in Q2 2025.